← boardnext 2028-08
PASG
Passage Bio, Inc.distress 4/10 · elevated risk$4.92+0%today-75% from 52w high
Lead: FTD-GRN
Revenue
pre-revenue
Liquidity
$33M
Runway
1.1 yrs
Shares 1y
+1%
Price & events
-61.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+0.2%
1W
-14.0%
1M
-19.7%
3M
-61.3%
6M
-13.2%
1Y
-71.7%
2Y
-98.1%
5Y
-99.1%
All
Overview
- Market Cap
- $15.78M
- Volume
- 34.00K
- 52 Week Range
- $4.08 – $19.85
- Total Shares
- 3.21M
- Float Shares
- 2.89M
- Short %
- 4.43%
- % Held by Insiders
- 7.72%
- % Held by Institutions
- 59.85%
- RVOL
- 0.29x
- Beta
- 1.42
Pipeline stages · 1 programs
PBFT02
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 1/2 | PBFT02fast trackorphan | Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72 | — | active not recruiting |
Catalyst news & presentations · 16
- 2H 2026Guided 55%readoutPBFT02 · Clinical candidate selection for Huntington's disease programSEC 8-K
- 1H 2026regulatory submissionFiled (NDA/BLA)PBFT02 · Seek regulatory feedback on registrational trial designSEC 8-K
- first half of 2026readoutPhase 1/2PBFT02 · Seek regulatory feedback on registrational trial design.SEC 8-K
- 2026-06-24partnershipEntry into Agreement and Plan of Merger with Remix and $100M concurrent financingSEC 8-K
- 2026-04-20fda agreementPBFT02 · FDA indicated a randomized controlled registrational trial is required for PBFT02 in FTD-GRN.SEC 8-K
- second half of 2025conferencedata presentationsecondaryPBFT02 · Seek regulatory feedback on suspension-based manufacturing process comparability.SEC 8-K
- July 2025regulatory submissionFiled (NDA/BLA)PBFT02 · Submit upliFT-D protocol amendment to health authorities.SEC 8-K
- 1H 2025readoutPhase 1/2PBFT02 · Report 12-month Cohort 1 and interim Cohort 2 data from upliFT-D trial.SEC 8-K
- first half of 2025trial initiationsecondaryPBFT02 · Initiate dosing of FTD-C9orf72 patients in upliFT-D trial expansionSEC 8-K
- 2025-06-23safety signalPBFT02 · Four SAEs in three patients: venous sinus thrombosis (2), hepatotoxicity, pulmonary embolism.SEC 8-K
- September 2024conferencedata presentationsecondaryPBFT02 · Interim safety and biomarker data from Cohort 1 of upliFT-D trial at ISFTD2024SEC 8-K
- 2024-08-08partnershipPBGM01, PBKR03, PBML04 · Out-licensed pediatric LSD programs to GEMMA BiotherapeuticsSEC 8-K
- 2024-08-08fda agreementPBFT02 · FDA alignment on expansion of upliFT-D trial to include FTD-C9orf72 patientsSEC 8-K
- 2024-07-31partnershipEntered research collaboration with Gemma for preclinical/IND-enabling work on Huntington's disease and Temporal Lobe Epilepsy programs (drug names not specified).SEC 8-K
- 2024-07-31partnershipPBML04 · Outlicensed to Gemma Biotherapeutics for metachromatic leukodystrophy with initial payments and potential milestones.SEC 8-K
- 2024-07-31partnershipPBKR03 · Outlicensed to Gemma Biotherapeutics for Krabbe disease with initial payments and potential milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $16 (+215% upside) · 2 analysts
- 2026-04-21TD CowenBuy → Hold
- 2026-04-21Chardan CapitalBuy → Neutral
- 2026-04-21OppenheimerOutperform
- 2026-04-21WedbushOutperform → Neutral
- 2026-03-31OppenheimerOutperform
- 2026-03-04Canaccord GenuityBuy
Competitors — FTD-GRN
- DNLIDenali Therapeutics Inc.$3.6B · D2
Recent news
- 2026-07-23PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
- 2026-07-22Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com South Africa
- 2026-07-21Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
- 2026-07-08Passage Bio Inc. (PASG) Rises 7.3% as Momentum Lifts Shares Above Key Support - Elliott Wave Count - DonanımHaber
- 2026-07-07Passage Bio (PASG) Surges 7.3% as Stock Tests Key Resistance at $5.25 - Sentiment Divergence - DonanımHaber
- 2026-07-07Passage Bio (PASG) Surges 7.3% as Stock Tests Key Resistance at $5.25 - Technical Analysis - dars.gov.et
- 2026-07-06PASG Q1 2026 Earnings: Narrowed Losses Beat Estimates as Clinical Progress Continues - Negative Surprise Momentum - dars.gov.et
- 2026-07-03Passage Bio explores gene therapy potential as investors weigh long-term prospects - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.